Drug regulators have approved a new weekly insulin injection for individuals with type 2 diabetes, offering a significant shift from the current daily regimen. The treatment, known as insulin efsitora alfa or Onswik, has demonstrated in trials the ability to stabilize blood sugar levels as effectively as daily insulin.
This development could alleviate the burden of frequent injections for hundreds of thousands of people in the UK who manage type 2 diabetes. The condition, which affects approximately 4.2 million people in the UK, occurs when the body does not properly utilize insulin, leading to dangerously high blood sugar levels and potential organ damage. About a quarter of those with type 2 diabetes require insulin injections to manage their condition, with some needing multiple doses per day.
The weekly jab is expected to be particularly beneficial for individuals who require assistance with injections, including those who are frail, have visual impairments, limited hand mobility, or learning disabilities. The National Institute for Health and Care Excellence (NICE) has deemed the treatment cost-effective, though NHS England has not yet announced plans for a widespread rollout.
Experts highlight that a move to a weekly dose could substantially improve the daily lives of patients, especially those who depend on caregivers or healthcare professionals for their injections. Diabetes UK has emphasized the need for clear guidance, staff training, and equitable access to ensure that all eligible individuals can benefit and make informed decisions about the treatment.
Concerns have recently been raised regarding an increase in younger individuals developing type 2 diabetes. A 2024 report indicated a 40 percent rise in patients under 40 over five years, with a notable 70 percent jump in diagnoses among women aged 20-29 in England over the past decade. Researchers attribute this trend partly to rising obesity rates. Meanwhile, diagnoses in older age groups have seen a decrease.